Onfi Approval Shows Benefits Of Lundbeck's Ovation Acquisition
This article was originally published in The Pink Sheet Daily
Clobazam is approved as an add-on to therapy for a particularly severe orphan seizure disorder known as Lennox-Gastaut syndrome.
You may also be interested in...
Labeling for Eisai’s Banzel, which also has an indication limited to Lennox-Gastaut syndrome, does not mention Stevens-Johnson syndrome or toxic epidermal necrolysis cited in the Onfi warning.
Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.